Results 1 to 4 of 4
his Goldmine currently trades below cash but this will change with the upcoming FDA Decision on 14th Feb . FDA approval will push this wayyy oversold goldmine back to $2++ easily ..
Buy now and make a lot of money with the runup to Fda decision folks .
TARGET 3-5 dollar in 2012 ! GLTA
Biosante (BPAX)
Market cap : $56 M
Cash : $ 70 M
Price: 0.515
(BPAX) Mcap 55 M /Cash 70 M /FDA DECISION 14 FEB 2012
Bio-T-Gel™ is a once-daily transdermal testosterone gel in development for the treatment of male hypogonadism, or low testosterone levels. Male hypogonadism generally is characterized by impotence, a lack of sex drive, muscle weakness and osteoporosis. In 2010, the transdermal testosterone market for men in the U.S. was over $1.2 billion.
Bio-T-Gel™ is licensed to Teva Pharmaceuticals, USA. A Bio-T-Gel™ NDA is pending with the FDA having a PDUFA date of February 14, 2012. Teva is responsible for all regulatory and marketing activities.
Hey I could use some of that! LOL
Are younbridingbfree shares going into the FDA decision. Those are risky beyond risk. I love em. If they go right you ride the wave and then short the snot out the stock. rebuy before they announce a marketing partner, then ridse the wave again and pay off te mortgage. Great nitch field, but does it work? The FDA is a bunch of anti capitalisim A-holes. I really hate the power they yield.
But on a more sober tone. What about this burp?
DNDN did something about like that and had a bad kick in the side of the head. They turned it around and rock'n today. The entire Sector is rocking. DNDN leads that arena.
The investigation stems from allegations that BioSante issued materially false and misleading statements designed to artificially inflate the Company's stock price. In particular, the investigation concerns allegations that senior officials at BioSante misled investors about the commercial viability and effectiveness of LibiGel, an experimental compound intended to boost women's libido. On December 14, 2011, the Company disclosed that its product LibiGel failed to yield positive results in efficacy tests. Upon this news, shares of BioSante stock plummeted from a trading high of $2.65 on December 14, 2011 to a close of $0.48 on December 15, 2011.
